Voluven - drug solution, belonging to the group of plasma substitutes. Used for parenteral administration. The active ingredient hydroxyethyl starch.
Structure and Composition
Voluven 1000ml solution containing 60 g of a base material (poly (0-2-hydroxyethyl) starch) and 9 g of sodium chloride.
It is produced in glass or plastic bottles of 250 ml, and 500, as well as bags for infusion solutions "frifleks" 250 and 500ml.
Pharmacological action Voluven
According to the instructions Voluven a plasma-solution. The main active ingredient (HES) in its structure similar to glycogen, it leads to a low risk of allergic reactions to the drug and its high tolerance (tolerance).
After intravenous administration of a single molecule Voluven it completely eliminated from the body within 24 hours. Research was conducted on volunteers, after which revealed that accumulation of the substance in the blood plasma, even when administered daily for 10 days does not occur.
Voluven is intended for the treatment and prevention of hypovolemia (blood volume reduction) and in hemodilution (normovolemic or therapeutic).
- intolerance to the ingredients of the drug;
- hyperhydration (excessive water content in the blood);
- hypervolemia (increase circulating blood volume or plasma);
- expressed disturbances of blood coagulation;
- increased intracranial pressure;
- severe degree of renal failure with oliguria or anuria (and, if the patient is on dialysis);
- state of dehydrated, requiring the introduction of water-salt solutions;
- severe heart failure.
Dosing and Administration
According to the instructions Voluven for continuous intravenous infusion. First introduced very slowly 10-20 ml of the product. At this time, the patient must be under medical supervision to prevent allergic reactions.
Adult Voluven maximum daily dose of 50 mL / kg per day.
For children, the maximum daily dose Voluven depends on the age of the child:
- Children 10 - 18 - 33 ml / kg;
- Children 2 - 10 years - 25 ml / kg;
- children up to 2 years (including newborn) - 25 ml / kg.
The duration of treatment depends on the severity Volyuvenom and duration of hypovolemia, the rate of recovery of hemodynamics. The drug can be administered repeatedly, given the necessary evidence.
Side effects Voluven
Allergic reactions to this drug are rare, in this case, the drug infusion should be stopped immediately.
With the introduction of Voluven can be observed increase in serum amylase, which complicates the diagnosis of pancreatitis. One of the common side effects of prolonged use of preparations based on hydroxyethyl starch - itching.
Appearance of blood coagulation disorders dependent on dose and duration of application.
Cautions and precautions
During the therapy with Voluven avoid excessive fluid administration. Especially the risk of fluid overload in patients with symptoms of congestive heart failure and severe renal impairment. Indications should be clarified prior to use of the drug.
In renal failure and blood coagulation disorders should be appointed Voluven caution. In this case it is important to ensure the patient a sufficient amount of the liquid control serum laboratory parameters.
Patients whose blood has not been determined prior to administration of the drug, it is necessary to take into account that the drug can affect the agglutination reaction (give false-positive results in the determination of blood groups).
For the treatment of premature babies Voluven can be used only after a thorough analysis of the risk / benefit ratio.
This drug should not be mixed with other drugs. In case of emergency, you must first check the compatibility (or if there is some sediment turbidity, the drugs can not be used together). According to the instructions Voluven should be used immediately after opening the bottle (bag). The unused solution remaining after infusion is prohibited to use!
Interaction Voluven with other drugs
Not reported on the interaction of the drug with other drugs.
Use during pregnancy and lactation
Research on the use of Voluven for treating pregnant women were not conducted. Clinical experiments on animals showed no adverse effects of the drug on the developing fetus. Signs of teratogenicity Voluven not been identified. Use of the drug during pregnancy is possible if the potential benefit outweighs the risk.
According to the instructions Voluven clinical data on its use in women during lactation are not available.
An overdose of the drug, as well as other means of plasma-may cause overloading of the circulatory system (for example, lead to pulmonary edema). In this situation it is necessary to stop the infusion and enter Voluven diuretic (if necessary).